Clinical efficacy of JAK inhibitors for RA patients with poor-prognosis factors: the ANSWER cohort study
Authors' conclusion
JAKi treatment provided sustained disease control (especially in high-risk RA patients) and promoted GC reduction.
Study context
- Population
- RA patients from the ANSWER cohort with poor-prognosis factors (ACPA or RF positivity, Clinical Disease Activity Index (CDAI) ≥22, CRP ≥0.6 mg/dl, HAQ-DI ≥0.5); categorized as 4PPFs or <4 PPFs
- Participants
- 1,794 patients
- Exposure
- JAKi vs TNFi in RA patients with poor-prognosis factors
- JAKin = 559
- TNFin = 1,235reference
- Outcome
- CDAI change, median
Methodological detailspropensity score matching
- Propensity score matching
Main finding
As reported in the abstract
JAKi
−23.3
median
TNFi
−19.9
median
Observational data: associations, not effects.
Further findings
Low disease activity achievement (4PPFs subgroup) · 24 months
GC discontinuation · 24 months
Cumulative GC discontinuation rate · 24 months
Low disease activity achievement (4PPFs subgroup) · 24 months
- Significantly higher with JAKi
Glucocorticoid (GC) dosage reduction over time (4PPFs subgroup)
- Greater (but nonsignificant) reduction with JAKi
Original publication
Clinical efficacy of JAK inhibitors for RA patients with poor-prognosis factors: the ANSWER cohort study. Rheumatology (Oxford). Published 22 October 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →